NCT00807963View on ClinicalTrials.gov

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

September 21, 2009

Study Completion Date

September 21, 2009

Conditions
Risk Factors for or a Diagnosis of Osteoporosis
Interventions
DRUG

rHuPH20

recombinant human hyaluronidase PH20 injection

DRUG

zoledronic acid

subcutaneous injection

Trial Locations (1)

78209

Healthcare Discoveries, LLC/ICON Development Solutions, San Antonio

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT00807963 - Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone | Biotech Hunter | Biotech Hunter